Galapagos NV (NASDAQ:GLPG)

54.79
Delayed Data
As of Jul 27
 -1.54 / -2.73%
Today’s Change
12.91
Today|||52-Week Range
59.19
+196.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.1B

Company Description

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company operates through two operating divisions: Research and Development and Services. The Research and Development division develops medicines based on novel mode-of-action. The Service division offers target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. The company was founded by Onno van de Stolpe and Rudi Pauwels in 1999 and is headquartered in Mechelen, Belgium.

Contact Information

Galapagos NV
Industriepark Mechelen Noord
Mechelen Brussels Region 2800
P:(321) 534-2900
Investor Relations:
(262) 291-6240

Employees

Shareholders

Mutual fund holders9.17%
Other institutional-9.13%
Individual stakeholders--

Top Executives

Onno van de StolpeChief Executive Officer & Executive Director
Bart FiliusChief Financial Officer
Piet WigerinckChief Scientific Officer
Andre HoekemaSenior Vice President-Corporate Development
Elizabeth GoodwinHead-Investor Relations & Corporate Communications

To view my watchlist

Not a member yet?

Sign up now for a free account